Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals (Nasdaq: LXRX) priced a public offering of 32,000,000 common shares at $1.30 per share for expected gross proceeds of $41.6 million, closing on or about Feb 2, 2026. Underwriters have a 30-day option for an additional 4,800,000 shares.
Concurrently, Lexicon agreed a private placement to an affiliate of Invus for approximately $41.1 million including common shares and Series B convertible preferred stock convertible into common shares. Proceeds are for R&D, working capital and general corporate purposes.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced on January 29, 2026 that it has commenced an underwritten public offering of common stock and will grant a 30-day option for additional shares.
Lexicon also intends a concurrent private placement to an affiliate of Invus under its preemptive right; proceeds are intended for R&D, working capital, and general corporate purposes. Jefferies and Piper Sandler are joint book-runners. A preliminary prospectus supplement will be filed with the SEC.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will ring the Nasdaq Closing Bell on January 27, 2026 to mark its 30th anniversary as a biopharmaceutical company. The ceremony at Nasdaq MarketSite begins at 3:45pm ET and will be broadcast live. Lexicon said it has built a differentiated pipeline of oral small-molecule therapies for cardiometabolic diseases and chronic neuropathic pain, citing late-stage opportunities and commercially available medication as part of its 30-year evolution and patient-focused mission.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced on January 21, 2026 that it completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for pilavapadin in diabetic peripheral neuropathic pain (DPNP).
The FDA raised no objections to advancing pilavapadin into Phase 3, which the company plans as two placebo-controlled, 12-week, two-arm registrational studies evaluating a 10 mg daily dose versus placebo. The Phase 3 primary endpoint will be change in average daily pain score (ADPS) from baseline to Week 12. The FDA did not require unexpected preclinical or clinical studies that would likely delay Phase 3 or a potential regulatory submission.
Viatris (Nasdaq: VTRS) announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates, the first market within Viatris territories to commercialize the drug, with additional launches planned across multiple countries over the next several years.
Inpefa is the first dual SGLT1/2 inhibitor approved to reduce risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits. Approval is supported by two Phase 3 trials (SOLOIST-WHF and SCORED; >11,800 patients) showing a 33% reduction in the composite endpoint in SOLOIST-WHF (up to 51% when initiated prior to discharge), 25% reduction in SCORED, and a 23% reduction in MACE, including 32% reduction in MI and 34% reduction in stroke.
Lexicon Pharmaceuticals (Nasdaq: LXRX) provided a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, and will present on January 15 at 12:00 p.m. PT (3:00 p.m. ET).
Key program timelines: the pivotal SONATA-HCM Phase 3 study of sotagliflozin targets enrollment completion in mid-2026 with topline results expected in Q1 2027. ZYNQUISTA® (sotagliflozin) for type 1 diabetes remains on track for an NDA resubmission and potential approval in 2026 contingent on STENO1 patient exposure and safety data. Pilavapadin advanced via an End-of-Phase 2 meeting and partnership discussions continue.
Commercial and finance: Lexicon triggered a $10 million milestone from Novo Nordisk for LX9851, has received $45 million to date with up to $950 million in remaining milestones plus tiered royalties, and ended 2025 with $125.2 million in cash, investments and restricted cash, which the company says supports operations into 2027 (excluding milestone impacts).
Lexicon Pharmaceuticals (NASDAQ: LXRX) published a white paper titled “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” summarizing findings from an October 2025 Roundtable of patients, clinicians, advocates, and other stakeholders.
The paper highlights that chronic pain affects one in four American adults, costs the U.S. >$720 billion annually (including ~$190 billion in lost productivity), and calls for swift policy action to expand access to novel non-opioid therapies, citing the recently introduced Relief of Chronic Pain Act.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 12:00 p.m. PT / 3:00 p.m. ET in San Francisco.
The company said the live presentation and replay will be available on its investor Events page at https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced publication of preclinical data on ACSL5 in the Journal of the Endocrine Society on Dec 10, 2025, reinforcing the rationale for its oral ACSL5 inhibitor LX9851. Animal studies showed ACSL5 knockout mice and mice given potent oral ACSL5 inhibitors had lower body weight and body fat, reduced triglycerides, total cholesterol and blood glucose, and preserved lean mass versus controls.
Mechanistic work linked effects to activation of the ileal brake, which delayed gastric emptying and reduced food intake. Lexicon holds an exclusive worldwide license for LX9851 with Novo Nordisk (March 2025).
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present clinical data on sotagliflozin's effect on adipose tissue distribution in non-diabetic patients with HFpEF at CVCT 2025.
The data derive from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial conducted by Mount Sinai Medical Center. The presentation is scheduled for Monday, December 8, 2025 at 10:30 a.m. ET and will be delivered by Juan Jose Badimon, Ph.D., at the 22nd Global Cardio Vascular Clinical Trialists Forum (December 8-10, 2025) at the Mayflower Hotel, Washington, D.C.
Lexicon highlighted this dataset alongside recent cardiac remodeling and MACE data as additional evidence of sotagliflozin's differentiated effects versus SGLT2 inhibitors.